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Objective: The authors investigated the
effects of recently identiﬁed genome-wide
signiﬁcant schizophrenia genetic risk var-
iants on cognition and brain structure.
Method: A panel of six single-nucleotide
polymorphisms (SNPs) was selected to
represent genome-wide signiﬁcant loci
from three recent genome-wide associa-
tion studies (GWAS) for schizophrenia and
was tested for association with cognitive
measures in 346 patients with schizophre-
nia and 2,342 healthy comparison sub-
jects. Nominally signiﬁcant results were
evaluated for replication in an indepen-
dent case-control sample. For SNPs show-
ing evidence of association with cognition,
associations with brain structural volumes
were investigated in a large independent
healthy comparison sample.
Results: Five of the six SNPs showed no
signiﬁcant association with any cognitive
measure. Onemarker in themajor histocom-
patibility complex (MHC) region, rs6904071,
showed independent, replicated evidence
of association with delayed episodic mem-
ory andwas signiﬁcant when both samples
were combined. In the combined sample
of up to 3,100 individuals, this SNP was
associated with widespread effects across
cognitive domains, although these addi-
tional associations were no longer signiﬁ-
cant after adjusting for delayed episodic
memory. In the large independent struc-
tural imaging sample, the same SNP was
also associated with decreased hippocampal
volume.
Conclusions: The authors identiﬁed
a SNP in the MHC region that was as-
sociated with cognitive performance in
patients with schizophrenia and healthy
comparison subjects. This SNP, rs6904071,
showed a replicated association with epi-
sodic memory and hippocampal volume.
These ﬁndings implicate the MHC region in
hippocampal structure and functioning,
consistent with the role of MHC proteins
in synaptic development and function.
Follow-up of these results has the potential
to provide insights into the pathophysiol-
ogy of schizophrenia and cognition.
(Am J Psychiatry 2013; 170:877–885)
In recent years, the advent of genome-wide association
studies (GWAS) has advanced the ﬁeld of complex disease
genetics, including that of major mental illnesses. The ﬁrst
truly large-scale GWAS in schizophrenia were published in
2009 by the International Schizophrenia Consortium (1),
the Molecular Genetics of Schizophrenia study (2), and
SGENE-plus (3), which also obtained additional data re-
sulting in a sample of up to 50,000 individuals (case sub-
jects and healthy comparison subjects). Taken together,
three regions of association were identiﬁed at the genome-
wide signiﬁcant threshold: 1) a region on chromosome
6p22.1 that includes themajor histocompatibility complex
(MHC); 2) the transcription factor 4 (TCF4) locus on
chromosome 18; and 3) the neurogranin (NRGN) locus on
chromosome 11. Although the association signals formally
implicate genomic regions rather than speciﬁc genes, the
roles of NRGN and TCF4 in brain function and de-
velopment (3–5) are compatible with the hypothesis that
increased risk for schizophrenia is related to altered
function of these genes. However, the association at
6p22.1 is within a region of exceptionally high linkage
disequilibrium (LD) spanning hundreds of genes, any of
which could contain the functional susceptibility variant
or variants. The identiﬁcation of causative variants is
made challenging by such high LD, although investi-
gators using conditional analysis have observed at least
two statistically independent associations in the MHC
region (3).
This article is discussed in an Editorial by McGufﬁn and Power (p. 821)
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The identiﬁcation of associated SNPs is only a ﬁrst step
toward elucidating the neurobiological pathways involved
in schizophrenia. Attaining this goal requires the func-
tional consequences of polymorphisms to be identiﬁed at
the level of the protein, cell, neural circuit, or alternative
human phenotypes. Studies of neurocognition and struc-
tural brain imaging offer a way of exploring the action of
polymorphisms on behavioral neural circuits at the whole
organism level (6). Widespread cognitive deﬁcits are char-
acteristic features of schizophrenia, and their amelio-
ration is increasingly seen as central to improving the
functional outcome of patients (7). In this study, we set out
1) to investigate the effects of GWAS-supported variants on
cognitive phenotypes in schizophrenia patients andhealthy
comparison subjects and replicate any associations, and
2) to investigate the relationships between variants with
cognitive effects and relevant brain structure volumes
using a sample that was independent from the cognitive
data collection sample. We previously reported results for
rs12807809 (NRGN locus) in a subsample of the individ-
uals included in this study (8). It should be noted that the
design of this study predates the publication by the
Psychiatric Genomewide Association Study Consortium




German sample. The German sample consisted of 346 patients
with a DSM-IV diagnosis of schizophrenia and 2,342 healthy
comparison subjects. Two hundred sixteen of the patients (62%)
and 545 of the comparison subjects (23%) formed part of the
SGENE-plus study (3). The patients were ascertained from mental
health services in the Munich area. Exclusion criteria were
a history of head injury or neurological disease. Patients, ages
18–80 years, were interviewed with the Structured Clinical
Interview for DSM-IV (SCID) (10), and the interviews were rated
by psychiatrists or psychologists.
Healthy comparison subjects of German descent, ages 18–80
years, were randomly selected from population registers from
the Munich area. Participants underwent an extensive screen-
ing process, described previously (11), to exclude those with
neurological or psychotic disorders and those who had ﬁrst-
degree relatives with psychotic disorders. In the case of
participants older than 60 years, the Mini-Mental State Exami-
nation (12) was employed to exclude individuals with possible
cognitive impairment.
Irish replication sample. The Irish sample consisted of 377
patients with schizophrenia and 145 comparison subjects. One
hundred three patients (but no comparison subjects) formed
part of the International Schizophrenia Consortium study (13).
Patients with schizophrenia, ages 18–65 years, were recruited
from across Ireland, and the diagnosis was conﬁrmed by trained
psychiatrists using the SCID (10). Comparison subjects, ages
18–65 years, were recruited by local media advertisements.
Exclusion criteria were the same as used in the German sample.
All patients with schizophrenia and comparison subjects were
unrelated white Caucasians of German or Irish ancestry. All
participants provided informed consent in accordance with the
relevant ethics approvals.
Cognitive Assessment
The study was designed by selecting tests to represent domains
of cognition that are known to be compromised in schizophrenia:
IQ, episodic memory, working memory, and attention/vigilance.
Given that we intended to seek replication of signiﬁcant results,
we selected identical or near identical tests within cognitive
domains for the German and Irish samples. The number of tests
and measures within each cognitive domain was limited to mini-
mize multiple testing, mirroring our previous research (11). The
German sample was used as a discovery sample, and marker-
phenotype combinations that were nominally signiﬁcant were
taken forward for replication in the Irish sample.
For the German sample, IQ was measured by the full German
Wechsler Adult Intelligence Scale–Revised (WAIS-R) (14). Epi-
sodic memory was assessed using the immediate and delayed
logical memory tests from the German Wechsler Memory Scale–
Revised (WMS-R) (15). Verbal and spatial working memory were
assessed using the digit span test from the WAIS-R and the
spatial span test from the WMS-R. Attention/vigilance was as-
sessed using the Continuous Performance Test, 3–7 Version (16).
Test results were available in up to 342 patients and 2,342 com-
parison subjects.
For the Irish sample, IQ was measured using selected subtests
(vocabulary, similarities, block design, and matrix reasoning)
from the Wechsler Adult Intelligence Scale, 3rd edition (WAIS-III)
(17). We measured episodic memory using the immediate and
delayed logical memory tests from the Wechsler Memory Scale,
3rd edition (WMS-III) (18). Working memory was measured using
the letter-number sequencing test from the WMS-III and the
spatial working memory test from the Cambridge Neuropsycho-
logical Test Automated Battery (19). Attention/vigilance was
measured using the three-letter condition of the Continuous
Performance Test, Identical Pairs Version (20), but an insufﬁcient
number of comparison subjects completed this task, making it
unavailable for this group. Test results were available for up to
377 patients and 148 comparison subjects. These procedures and
the selected tests reproduce our previous research (11).
Selection of SNPs.We identiﬁed a nonredundant panel of SNPs
representing all genome-wide signiﬁcant signals from the com-
bined studies of the International Schizophrenia Consortium
(13), Molecular Genetics of Schizophrenia (2), and SGENE-plus
(3). Among the multiple correlated signals at chromosome 6, we
selected the most signiﬁcantly associated variant from the In-
ternational Schizophrenia Consortium and Molecular Genetics
of Schizophrenia studies, rs13194053. In the German sample, we
typed rs6904071, a perfect proxy for rs13194053 according to
HapMap. In the SGENE-plus study, rs6932590 was the most
signiﬁcantly associated variant and was included in our panel.
Also from that study, analysis conditioned on rs6932590 further
revealed a strong, statistically independent signal at rs3131296 and,
independent of both of these markers, a weak association signal
at rs13219354; both of these SNPs were included in our analysis.
We also selected the genome-wide signiﬁcant SNPs at NRGN
(rs12807809) and TCF4 (rs9960767) as reported by SGENE-plus.
We therefore analyzed the associations with cognition for
a panel of six SNPs in total. The four individual MHC SNPs were
not in high LD (1,000 genomes, r2,0.8) and covered the statis-
tically independent schizophrenia association signals that were
identiﬁed in this region.
Genotyping
The SNPs were genotyped in the German sample and in a
proportion of the Irish sample using the Sequenom iPLEX Gold
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system. The call rate for this genotyping was .95% in both sam-
ples. The remainder of the Irish sample was genotyped using a
Taqman SNP Genotyping Assay on a 7900HT Sequence Detection
System (Applied Biosystems). The call rate for the Taqman geno-
typing was .95%. For all genotyping, both patient and compari-
son samples were in Hardy-Weinberg equilibrium for all SNPs
(p.0.05).
Statistical Analysis
The association between markers and cognitive phenotypes
was tested using linear regression, assuming an additive model,
using SPSS, version 14 (21). Genotypes and patient/comparison
status were entered as independent variables, and age and
gender were entered as covariates when appropriate (i.e., unless
scaled test scores were used). Linear regression was also per-
formed in patient and comparison samples separately in order to
examine differential effects between case and comparison sub-
jects. Markers with nominally signiﬁcant associations (p#0.05) in
the German sample were taken forward for replication in the
Irish samples. For signiﬁcant markers, we also performed a case-
control logistic regression analysis within the German discovery
and Irish replication cohorts.
In addition to seeking replication, we combined the German
and Irish samples to examine the association between SNPs and
combined cognitive domain test scores in as large a sample as
possible. We derived standardized z scores for each of the
cognitive tests separately in each sample. These scores were then
combined for equivalent tests across the two samples to give
study-wide cognitive domain z scores. Linear regression was
used in the combined sample using z scores as the dependent
variable and genotype as the independent variable, adjusting for
case status, age, and gender as appropriate.
The power of this design varies depending on the selected
polymorphism and cognitive test. However, as an example, the
German comparison sample has 80% power to detect a risk allele
accounting for 0.34% of variance in IQ at the 5% signiﬁcance
threshold.
Structural Imaging Analysis
For those SNPs demonstrating a replicated association with
cognition, we examined associations with cortical structure
volumes that were derived from structural MRI. The imaging
sample was part of the Brain Imaging Genetics project; a full
description of the sample and procedures for genotyping and
neuroimaging is provided in detail elsewhere (22). Brieﬂy, 892
white Caucasian healthy young adults (369 men and 523 women;
ages 18–35 years) underwent structural MRI and provided saliva
samples that were genotyped using the Affymetrix GeneChip
SNP, 6.0 array; genotypes were imputed using the MaCH
software package (23). MRI acquisition was on 1.5-T (N=416)
and 3-T (N=476) scanners, and segmenting into gray and white
matter was performed with the VBM 5.1 toolbox, version 1.19,
with the SPM software package (22). Informed by the neuro-
cognitive tests and available imaging structural phenotypes, we
chose to analyze total gray matter volume and total hippocampal
volume. Gray matter volume was chosen because several of the
cognitive tests involve generalized cognitive functioning or are
reliant on multiple, rather than speciﬁc, brain regions. Hippo-
campal volume was chosen as a brain structure that has speciﬁc
relevance to aspects of cognition tested, particularly episodic and
spatial memory. Prefrontal structural volumes would have been
of interest given our cognitive battery but were unavailable for
this analysis. Using linear regression, SNPs that were signiﬁcantly
associated with cognition were assessed for association with
these brain structural volumes. The analyses were adjusted for
ﬁeld strength, age, and gender; the analysis of hippocampal
volume was corrected for total brain volume, and the analysis of
gray matter volume was corrected for total white matter volume.
Results
Association With Cognition
German sample. The results from the German data set are
summarized in Table 1. As expected, patients with
schizophrenia performed signiﬁcantly below comparison
subjects on all administered cognitive tests. Of the six SNPs
examined, only one (rs6904071; equivalent by r2=1 to
rs13194053, the top hit in the International Schizophrenia
Consortium and Molecular Genetics of Schizophrenia
studies) showed a nominally signiﬁcant association with
any of the cognitive tests. For the nonsigniﬁcant SNPs,
genotypemean scores for the cognitive tests of IQ, working
memory, episodic memory, and attention/vigilance are
presented in Tables S1–S5 in the data supplement that
accompanies the online edition of this article.
The detailed results for the signiﬁcantly associated
marker, rs6904071, in the German sample are presented
in Table 2 (and as part of Figure 1). Nominally signiﬁcant
associations were foundwith IQ (B=1.060, p=0.046), spatial
working memory (B=0.448, p=0.049), delayed episodic
memory (B=1.488, p=0.011), and attention (B=0.15,
p=0.001). Notably, for all cognitive tests, individuals
homozygous for the schizophrenia risk G allele performed
more poorly than heterozygotes, who in turn performed
more poorly than nonrisk A homozygotes.
Irish replication sample. The SNP rs6904071, which showed
signiﬁcant associations with cognition in the German
sample, was taken forward for replication (Table 3). As-
suming a conservative one-tailed alpha of 0.0125 (0.05/4
[4=number of tests that were signiﬁcant in the German
sample]), the delayed episodic memory test displayed
signiﬁcant replication (WMS delayed logical memory; see
Tables 2 and 3 and Figure 1). This association was in the
same allelic direction as in the German sample, that is, the
schizophrenia risk G allele was associated with worse
performance in delayed episodic memory.
The detailed results of the separate patient and com-
parison group analyses in both the German and Irish
samples are provided in Table S6 in the online data
supplement.
We also examined whether this SNP, rs6904071, was
associated with schizophrenia in the two samples. The
SNP was nominally associated with schizophrenia in the
Irish sample (odds ratio=1.49, p=0.023) but was not
signiﬁcantly associated with schizophrenia in the German
sample (odds ratio=1.11, p=0.33). Notably, the allelic
direction of association was the same in both samples
and mirrored that in the original GWAS studies (although
there was sample overlap as outlined above).
Combined sample. Table 4 summarizes the results for the
combined analysis. This analysis conﬁrms an association
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between rs6904071 and ﬁve of the six cognitive tests at
a nominally signiﬁcant level. Notably, the combined anal-
ysis results indicate association with delayed episodic
memory and attention/vigilance at a level that would
survive adjustment for multiple testing of all six SNPs and
six cognitive tests (p,0.0014). Table 4 also outlines the
results for schizophrenia patients and healthy comparison
subjects considered separately. rs6904071 was associated
with performance on cognitive measures in both patients
and comparison subjects.
Because the replicated ﬁnding and the most signiﬁcant
association in the combined analysis was for delayed
episodic memory, we repeated the combined analysis for
the other cognitive domains while adjusting for delayed
episodic memory to investigate whether the other cogni-
tive associations were independent of the association with
this cognitive domain. The sample for the adjusted an-
alysis was smaller (maximum N=1,161), but rs6904071 re-
mained signiﬁcantly associated with the same cognitive
domains in this sample in unadjusted analyses. However,
after adjusting for delayed episodic memory performance,
none of the other cognitive domains remained signiﬁcantly
associated (see Table S7 in the online data supplement for
results of this analysis).
The association of rs6904071 genotype with demo-
graphic and clinical variables in both samples is summa-
rized in Table S8 in the online data supplement. No
signiﬁcant differences in age, gender distribution, and
education by genotype were found in patients or compar-
ison subjects in either sample. Furthermore, in patients,
no signiﬁcant differences were observed between geno-
type groups in antipsychotic medication dosage in either
sample.
Structural Imaging
As the only signiﬁcant SNP to emerge from the analysis
with cognition, rs6904071 alone was taken forward to the
structural imaging analysis. This SNP was signiﬁcantly














SNP B p B p B p B p B p B p
rs6904071 1.060 0.046 0.242 0.077 0.448 0.049 0.553 0.284 1.488 0.011 0.150 0.001
rs13219354 0.968 0.138 0.033 0.847 0.200 0.474 20.275 0.663 0.525 0.465 0.102 0.063
rs3131296 20.107 0.866 20.044 0.790 20.369 0.219 0.563 0.403 0.615 0.423 0.107 0.067
rs6932590 0.909 0.056 0.131 0.284 0.362 0.081 20.335 0.473 0.002 0.997 0.077 0.053
rs9960767b 0.537 0.555 0.405 0.085 20.100 0.794 20.201 0.814 0.177 0.856 20.127 0.073
rs12807809 21.03 0.060 20.104 0.460 20.064 0.791 0.309 0.570 20.276 0.656 0.003 0.950
a Positive regression coefﬁcient indicates schizophrenia risk allele associated with worse performance on cognitive test. Nominally signiﬁcant p
values were taken forward for replication.
b For loci with minor allele frequencies ,0.1, the analysis was redone by grouping together minor allele and heterozygote genotype groups.
The results remained unchanged and none were signiﬁcant.
TABLE 2. Detailed Results for rs6904071 in the German Sample in a Study of Single-Nucleotide Polymorphism Associations
With Cognitive Domains
Cognitive
Function Test or Subscalea Sample N
AA AG GG
Regression




Full-scale IQ Patients 342 106.5 17.8 100.8 17.7 99.3 18.5 1.060 0.020–2.101 0.046
Comparison 2,244 114.5 13.9 113.8 14.5 113.0 14.5
Verbal working
memory
WAIS digit span Patients 342 16.4 4.6 14.0 3.5 13.3 3.7 0.242 20.026 to 0.511 0.077





Patients 239 18.5 3.73 15.3 2.98 14.91 3.40 0.448 0.002–0.895 0.049






Patients 240 29.2 8.6 24.8 8.2 23.9 9.0 0.553 20.461 to 1.566 0.284





Patients 239 30.0 11.5 28.8 9.4 25.8 10.5 1.488 0.341–2.635 0.011





Patients 346 4.59 0.67 4.28 0.83 4.10 0.95 0.150 0.063–0.236 0.001
Comparison 517 4.90 0.49 4.85 0.56 4.71 0.58
a WAIS=Wechsler Adult Intelligence Scale; CPT-IP=Continuous Performance Test, Identical Pairs Version; WMS-R=German Wechsler Memory
Scale–Revised. Raw scores are provided for WMS-R tests; all other scores are scaled.
b B coefﬁcient with respect to schizophrenia risk allele (G) adjusted for age and sex as appropriate.
c Nominally signiﬁcant association results taken forward for replication in Irish sample.
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associated with total hippocampal volume (B=0.080;
95% conﬁdence interval [CI]=0.006–0.154, p=0.035) and
with total gray matter volume (B=25.93; 95% CI=20.37
to 211.49, p=0.036). The schizophrenia risk allele, which
was associated with worse cognition, was associated with
smaller hippocampal volume, which was the predicted
direction of association. The ﬁnding for gray matter was in
the counterintuitive direction, in that the risk allele was
associated with increased gray matter volume.
Discussion
At the time this study was conducted, the polymor-
phisms that we examined represented all of the genome-
wide signiﬁcant common variants thus far reported for
schizophrenia, with the exception of rs1344706 at ZNF804A,
on which we have previously reported (11). In taking the
GWAS results forward to examine their effects on cognition,
we sought to overcome the limitations of previous cognitive
and genetic studies by testing SNP associations with a priori
selected cognitive tests in large samples of healthy subjects
and schizophrenia patients and by seeking replication of
results in a sample with equivalent tests. Despite this
design, we failed to show any association with cognition for
ﬁve of the six schizophrenia risk SNPs tested. TCF4 and
NRGN are good candidate genes for cognition given their
putative roles in neurodevelopment and the processes
involved in cognition (4, 5). It is therefore of particular
interest that neither of these risk variants was associated
with cognitive performance in this study. Given that our
study had the power to detect an allelic effect accounting
for 0.3% of variance in IQ in the German comparison
sample alone, it is unlikely that these alleles have effects of
this magnitude on human cognition, although we cannot
exclude smaller effects.
This lack of effect at the behavioral and cognitive level
for the majority of the tested SNPs is perhaps to be
expected, given recent evidence that the overlap between
the genetics of schizophrenia and cognition is less than
previously proposed and that the majority of the genetic
variance for schizophrenia does not overlap with that of
cognition (24, 25). This is in keeping with other research
suggesting a limited role in cognition for commoncandidate
variants for schizophrenia (26).
The strongest evidence we obtained for an association
between schizophrenia risk alleles and cognitive measures
was for SNP rs6904071, in theMHC region. The association
was in the predicted direction—that is, the schizophrenia
risk allele was associated with poorer cognition. The
replicated association of this SNP with cognition was for
the domain of delayed episodic memory. That phenotype
was evaluated in the German and Irish samples using
precisely the same test (delayed logical memory). The lack
of replication for other cognitive domains may be due to
a lack of formal equivalence between the domain tests in
the two samples or as a result of the relatively smaller size of
the Irish replication sample. To counter the sample size
limitation, we combined data across both samples using z
scores for equivalent tests, and we demonstrated nominal
association with ﬁve of the six cognitive domains in the
combined sample. However, in follow-up adjusted analy-
ses, the signiﬁcant associations for the other cognitive
domains could have been explained by the association with
delayed episodic memory. This would suggest that the
effect on cognition of whatever functional variant is tagged
by rs6904071 is through biological pathways involved in
episodic memory. It follows that the same pathways could
be involved in the action of this polymorphism on elevated
schizophrenia risk, although the possibility of pleiotropy
cannot be ruled out by our analysis.
FIGURE 1. Delayed Episodic Memory Scores in German and
Irish Patients With Schizophrenia and Healthy Comparison




































































A. German Discovery Sample





a WMS-R= German Wechsler Memory Scale–Revised; WMS-III=Wechs-
ler Adult Intelligence Scale, 3rd edition.
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By an order of magnitude, delayed episodic memory
was the most strongly associated cognitive domain, and
rs6904071 was associated with performance in this
domain in both patients and comparison subjects. Per-
formance on the delayed logical memory test is known
to be sensitive to hippocampal pathology and resection
(27, 28) and is correlated with hippocampal volume in
clinical samples (29) as well as in the relatives of patients
with schizophrenia (30). Thus, our ﬁnding of association
with decreased hippocampal volume links rs6904071 to
both structure and function. Given the known prior
relationship between the cognitive and structural phe-
notype, the fact that we observed an association with
hippocampal structure in a sample independent of the
sample from which the cognitive measures were ob-
tained provides independent validation of the asso-
ciations. This ﬁnding adds to the evidence suggesting
an association between SNPs in the MHC region and
structural brain volumes, including the hippocampus
(31, 32).
TABLE 3. Results for rs6904071 in the Irish Replication Sample in a Study of Single-Nucleotide Polymorphism Associations
With Cognitive Domains
Cognitive
Function Test or Subscalea Sample N
AA AG GG
Regression






Patients 300 92.5 19.3 91.5 18.0 90.5 18.1 1.389 21.592 to 4.369 0.180









Patients 365 21.08 0.92 20.97 1.29 20.96 1.34 0.005 20.188 to 0.199 0.478






Patients 377 6.5 3.3 7.7 3.2 7.0 3.3 0.575 0.083–1.067 0.011
Comparison 145 16.2 1.6 13.4 2.5 13.0 2.6
Attention/
vigilance
CPT-IP (3 letters) Patients 257 2.27 1.5 1.97 0.87 1.95 1.04 0.031 20.209 to 0.271 0.399
Comparison n/a
a Scaled test scores. WMS-III=Wechsler Memory Scale, 3rd edition; CPT-IP=Continuous Performance Test, Identical Pairs Version.
b B coefﬁcient with respect to schizophrenia risk allele (G) adjusted for age and sex as appropriate.
c One-sided p value of regression.
TABLE 4. Association of rs6904071 With z Scores of Cognitive Domains in Combined German and Irish Samples
Cognitive
Function Participants








Patients 642 0.072 0.006–0.139 0.034 0.113 20.040 to
0.265





Patients 711 0.053 20.020 to
0.126





Patients 604 0.073 20.057 to
0.203
0.269 0.025 20.178 to
0.127







Patients 620 0.093 20.027 to
0.213
0.128 0.104 20.035 to
0.243









Patients 603 0.148 0.040–0.257 0.007 0.180 0.010–0.349 0.038 0.164 0.063–0.265 0.001
Comparison 517
a Adjusted for diagnostic status.
b Full-scale IQ in German sample and abbreviated IQ in Irish sample.
c Wechsler Adult Intelligence Scale digit span in German sample and letter-number sequencing in Irish sample.
d Wechsler Memory Scale spatial span in German sample and Cambridge Neuropsychological Test Automated Battery spatial working memory
in Irish sample.
e Immediate logical memory in both samples.
f Delayed logical memory in both samples.
g 3–7 version of the Continuous Performance Test used in German sample and three-letter version of the Continuous Performance Test,
Identical Pairs Version, used in Irish sample.
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rs6904071 was also associated with increased gray mat-
ter volume. The interpretation of this result is not as
straightforward as the hippocampal ﬁnding and may well
be a false positive ﬁnding as a result of chance. While
schizophrenia is typically associated with decreased gray
matter volume, other neurodevelopmental disorders, such
as autism, may be characterized by increased gray matter
volume, particularly in individuals with low IQ (33). An
inverse relationship between structural volume and per-
formance has been posited for various cognitive abilities
(34), although whether this proves relevant for the as-
sociation between rs6904071 and gray matter volume will
require further exploration.
The associated SNP (rs6904071) lies within the extended
MHC region on chromosome 6. The prospect of this region
harboring genetic risk variants for schizophrenia has long
been recognized (35) and has some support in research (9,
36, 37). Despite this, the association between the MHC
region and schizophrenia has been criticized as likely
a result of population stratiﬁcation (38). To counter this
criticism, our study used a subset of participants in the
German sample for whom genome-wide genotyping
was available (N=1,171) and derived principal compo-
nents using the Eigenstrat method (39). The association
between rs6904071 and cognition was robust to the
addition of one, two, or three principal components,
none of which affected the estimated effect size for any
of the cognitive tests (see Table S9 in the online data
supplement). This indicates that population stratiﬁca-
tion is unlikely to explain these results, particularly
when taken together with the ﬁnding of replication in
an independent sample.
It is possible that the association between schizophrenia-
associated markers at the MHC region and cognition and
brain structure may implicate altered immune function in
each of these phenotypes. Of over 160 genes in the MHC
region, roughly 30% are immune related, and the region has
been implicated in numerous immune-related diseases (40).
The possible link between immune function and schizo-
phrenia is reinforced by evidence suggesting co-segregation
between a range of autoimmune conditions and schizo-
phrenia (41).
However, in addition to immune-related explanations,
there are alternative potential mechanisms underpinning
the associations we have observed. Our signal lies within
the MHC class I region. MHC class I proteins have an
established role in adaptive immunity, but ﬁndings also
point to an involvement of this complex in synaptic de-
velopment and plasticity (42). Speciﬁcally, MHC class I
inﬂuences hippocampal long-term potentiation (43), pro-
viding a potential link between rs6904071, altered hippo-
campal structure and function, and amajor mechanism of
learning and memory. Furthermore, MHC class I protein
expression co-localizes postsynaptically with postsynaptic
density protein 95 in dendrites of the hippocampus and
has been found to play a role in synaptic morphology and
function (44). In the absence of evidence that the asso-
ciations we have observed reﬂect altered function at MHC
class I, we mention this as a caution against assuming
that the association implicates immunity. Given the LD
structure at this region, identifying the direct pathophys-
iological implications of the genetic associations will prove
challenging.
To summarize, in following up genome-wide signif-
icant schizophrenia loci, we have demonstrated that the
most signiﬁcant risk variant from the International
Schizophrenia Consortium and Molecular Genetics of
Schizophrenia studies (1, 2) is associated with cogni-
tion, speciﬁcally delayed episodic memory. We have
also both replicated this ﬁnding and shown that the
same allele is associated with hippocampal volume in
a manner consistent with known relationships between
cognition and hippocampal structure. The associated
polymorphism is in the MHC region, but until the
source of the association signal is more precisely id-
entiﬁed, it is impossible to adjudicate between several
theoretically plausible mechanisms linking the associ-
ation to schizophrenia and cognition in the MHC. The
ultimate resolution of this question has the potential to
indicate novel mechanisms linking cognitive deﬁcits to
schizophrenia.
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